

AMENDMENTS

In the Claims

Cancel Claim 1 and rewrite as new Claim 9.

--9. (New) A recombinant or isolated nucleic acid molecule encoding at least a biologically functional part of a mammalian protein capable of binding to a p53 protein and comprising at least a part of the sequence

```
1 GTGGCTCTTG CGAACTCTGG GTTTGAGAGG CCGGAACTGG TGCTGCCGTT
51 GCTCGCAGTT TCAAAATGCA GTGCAGGCCT TAGGGTCTCC GGCTGCCACC
101 CCTCCCCCAG CTAGGAGGGG GAGCGACTCA TGGAGCGGCC GTAAGTTTGC
151 TAACTGTGGA GTCTTCACTG CCAAAATGAC ATCACATTCC ACCTCGGCCC
201 AGTGTTTCAGC ATCTGACAGT GCTTGCAGAA TTCTTTCGGA ACAAATTAGT
251 GAGGTGCCGC CAAAACTGCA GCTTTTGAAG ATTTTGCATG CAGCAGGTGC
301 GCAGGGGGAA GTATTACCA TGAAAGAGGT AATGCACTAT CTAGGCCAGT
351 ATATAATGGT GAAGCAGCTC TATGATCAAC AGGAGCAACA TATGGTATAC
401 TGTGGTGGAG ATCTTTTGGG AGATCTACTT GGATGTCAGA GCTTTTCTGT
451 GAAAGATCCA AGCCCTCTCT ATGACATGCT AAGAAAGAAT CTTGTTACAT
501 CAGCTTCTAA TAACACAGAT GCTGCTCAGA CTCTCGCTCT CGCACAGGAT
551 CACACTATGG ATTTTCCAAG TCAAGACCGA CTGAAGCACG GTGCAACAGA
601 ATACTCCAAT CCCAGAAAAA GAACTGAAGA AGAGGATACT CACACTACTGC
651 CTACCTCACG ACATAAATGC AGAGACTCCA GAGCAGATGA AGACTTGATA
701 GAACATTTAT CTCAAGATGA GACATCTAGG CTTGACCTTG ATTTTGAGGA
751 GTGGGACGTT GCTGGCCTGC GTTGGTGGTT TCTAGGGAAT TTGAGAAACA
801 ACTGTATTCC TAAAAGTAAT GGCTCAACTG ATTTACAGAC AAATCAGGAT
851 ATAGGTACTG CCATTGTTTC AGACACTACG GATGATTTGT GGTTTTTTAAA
901 TGAGACCGTG TCAGAGCAAT TAGGTGTTGG AATAAAAAGTT GAAGCTGCTA
951 ATTCTGAGCA AACAAAGTGAA GTAGGGAAAA CAAGTAACAA GAAGACGGTG
1001 GAGGTGGGAA AGGATGATGA TCTTGAGGAC TCCAGGTCCT TGAGCGATGA
1051 TACTGACGTG GAACTTACCT CTGAGGATGA GTGGCAGTGT ACGGAATGCA
1101 AGAAGTTTAA TTCTCCAAGC AAGAGGTACT GTTTTCGTTG CTGGGCCTTG
1151 AGAAAGGATT GGTATTTCGGA TTGTTCTAAA TTAATTCATT CCCTATCTAC
1201 ATCTAATATT ACTGCCATAC CTGAAAAGAA GGACAATGAA GGAATTGATG
1251 TTCCCGATTG TAGGAGAACC ATTTTCAGCTC CTGTTGTTAG GCCTAAAGAT
1301 GGATATTTAA AGGAGGAAAA GCCCAGGTTT GACCCTTGCA ACTCAGTGGG
1351 ATTTTGTGGAT TTGGCTCATA GTTCTGAAAG CCAGGAGATC ATCTCAAGCT
1401 CGAGAGAACA AACAGATATT TTTTCTGAGC AGAAAGCTGA AACAGAAAGT
1451 ATGGAAGATT TCCAGAATGT CTTGAAGCCG TGTAGCTTAT GTGAAAAAAG
1501 GCCTCGGGAT GGGAACATTA TTCATGGGAA GACGAGCCAT CTGACGACAT
1551 GTTTCCTACTG TGCCAGGAGA CTGAAGAAGT CTGGGGCTTC GTGTCCTGTT
1601 TGTAAGAAAG AGATTTCAGTT GGTTATTAAA GTTTTATAG CATAGTTGAG
1651 TCAGTCACAG AGAAATACTA GGAGGACCAG GTCATTTATC AAAAAAAAAA
1701 A
```

or a functional equivalent thereof.--.

2. (Amended) [A] The nucleic acid molecule according to claim 9 which is a cDNA.
3. (Amended) [A] The nucleic acid molecule according to claim 9 or claim 2, encoding at least a functional part of [the] a human equivalent of [the] said sequence [of claim 1].
4. (Amended) A recombinant vector comprising a nucleic acid molecule according to claim [1-3 together with] 9 operatively linked to suitable elements for regulation of at least one of replication [and/or] and expression of said nucleic acid molecule.
5. (Amended) A recombinant host cell comprising a recombinant vector according to claim 4 [or a nucleic acid molecule according to anyone of the foregoing claims].
6. (Amended) An isolated or recombinant proteinaceous substance comprising at least a biologically functional part of an amino acid sequence resulting from the translation of a nucleic acid molecule according to [any one of claims 1-3, the expression of a vector according to claim 4 and/or the culture of a cell according to claim 5] claim 9.
7. (Amended) A method for the identification of [proteins] a protein having a binding affinity for p53 comprising the steps of:
[labelling a proteinaceous substance comprising at least the binding site of a p53 protein and] hybridizing [said] a labelled proteinaceous substance comprising at least the binding site of a p53 protein with [the] a protein to be tested; and
determining whether said protein has hybridized to said substance, whereby a protein having a binding affinity for p53 is identified.
8. (Amended) A method for the identification of a nucleic acid [molecules] molecule encoding [proteins] a protein having a binding affinity for a p53 protein comprising the steps of:
[expressing said nucleic acid in a suitable expression system, labelling a proteinaceous substance comprising at least the binding site of a p53 protein and] hybridizing [said] a labelled

proteinaceous substance comprising at least the binding site of a p53 protein with [the] a protein encoded by a nucleic acid to be tested, wherein said protein is produced by expressing said nucleic acid in a suitable expression system; and

determining whether said protein has hybridized to said substance, whereby a nucleic acid molecule encoding a protein having a binding affinity for p53 is identified.

Add the following new claims.

--10. (New) A recombinant host cell comprising a nucleic acid molecule according to claim 9.

11. (New) An isolated or recombinant proteinaceous substance comprising at least a biologically functional part of an amino acid sequence resulting from the translation of an expression of a vector according to claim 4.

12. (New) An isolated or recombinant proteinaceous substance comprising at least a biologically functional part of an amino acid sequence resulting from growing a recombinant host cell according to claim 5.--.

REMARKS

Claim 1 has been rewritten as new Claim 9 to correct a typographical error (two nucleotides appeared in lower case instead of upper case). The remaining amendments are to put the claims from the PCT application into traditional US format or to improve readability. No new matter is added by the above amendments and the Examiner is requested to enter the amendments.

Respectfully submitted,

Date: December 5, 1997



Barbara Rae-Venter, Ph.D.

Reg. No. 32,750

Rae-Venter Law Group, P.C.

P.O. Box 60039

Palo Alto, CA 94306

Telephone: (650) 328-4400

Facsimile: (650) 328-4477

BRV/amp INGE.006.00US PRELIM AMEND 120597